Resumen:
Background: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor
monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to
a higher rate of neurocognitive impairment.
Methods: In this observational, cross-sectional study we included patients with plasma virological suppression ($1 year)
without concomitant major neurocognitive confounders, currently receiving for $1 year boosted lopinavir or darunavir as
monotherapy or as triple ART. Neurocognitive impairment was defined as per the 2007 consensus of the American
Association of Neurology. The association between neurocognitive impairment and protease inhibitor monotherapy,
adjusted by significant confounders, was analysed.
Results: Of the 191 included patients - triple therapy: 96, 1–2 years of monotherapy: 40 and .2 years of monotherapy: 55 -
proportions (95% CI) with neurocognitive impairment were: overall, 27.2% (20.9–33.6); triple therapy, 31.6% (22.1–41.0);
short-term monotherapy, 25.0% (11.3–38.7); long-term monotherapy: 21.4% (10.5–32.3); p = 0.38. In all groups,
neurocognitive impairment was mildly symptomatic...